Schuchat Anne, Bell Beth P
National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Mailstop E-05, Atlanta, GA 30333, USA.
Expert Rev Vaccines. 2008 May;7(4):437-56. doi: 10.1586/14760584.7.4.437.
Although vaccines are studied intensively before licensure, insight into important aspects of vaccine performance and the effectiveness of immunization programs and policies can only be detected after vaccines enter widespread use. Now that 17 diseases are targeted for prevention through routine immunizations in the USA, reassessment of the nation's vaccine-preventable disease-monitoring efforts is appropriate. Postlicensure disease monitoring has permitted recognition of indirect protection, vaccine effectiveness of various schedules, duration of protection, health disparities, importation patterns and microbial adaptation. The investments in vaccine research, development and regulatory procedures prelicensure, as well as resources devoted to purchase, distribution and delivery of vaccines after introduction, necessitate strategic efforts to monitor the impact of large-scale use of vaccines on disease over time.
尽管疫苗在获得许可前会经过深入研究,但只有在疫苗广泛使用后,才能洞察疫苗性能的重要方面以及免疫规划和政策的有效性。鉴于在美国有17种疾病通过常规免疫进行预防,对国家疫苗可预防疾病监测工作进行重新评估是恰当的。疫苗许可后疾病监测已使人们认识到间接保护、不同接种程序的疫苗效力、保护期限、健康差异、输入模式和微生物适应性。在疫苗许可前对疫苗研究、开发和监管程序的投入,以及在疫苗引入后用于购买、分发和配送疫苗的资源,都需要做出战略努力,以长期监测大规模使用疫苗对疾病的影响。